roundhill glp-1 & weight loss etf and Weight-Loss Drug Demand Could Boost Returns for This HRTS: Effectively Thinning Investor Portfolios

Accurate documentation and coding of amputation level, laterality, and complications directly impacts RAF scores for Medicare Advantage plans

01, 2022, Academic Press

FLOW trial stopped early due to evidence of renal protection with semaglutide

2019;29:91731 e4

Taken together , our model predicts that the best candidates for adding GLP-1 M as a second line T2D medication are: older age, non-Asian subjects, with short T2D duration that have elevated HbA1C, high BMI, hypertension, and no heart failure or retinopathy

Next, we studied 380,438 patients without diabetes who were prescribed a GLP-1 or other weight loss medication and who had a visit between January 1, 2017, and October 31, 2024